How soon after HIV seroconversion is antiretroviral therapy initiated?

AIDS

Volumn 13, Issue 10, 1999, Pages 1241-1247

  Porter, K ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral therapy; Cohort; Seroconverters; Time to event

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TIME FACTORS;

EID: 0032811571     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00014     Document Type: Article

References (37)

1. 1. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
2. 2. Gazzard B, Moyle G, BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998, 352:314-316.
3. 3. International AIDS Society - USA panel. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society - USA panel. J Am Med Assoc 1998, 280:78-86.
4. 4. St Clair MH, Pennington KN, Rooney J, Barry DW. In vitro comparison of selected triple drug combinations for suppression of H1V-1 replication: the Inter Company Collaboration Protocol. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10(Suppl. 2): S83-S91.
5. 5. Pagano PJ, Chong KT. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U 90152) with protease inhibitor U-75875 or interferon alpha. J Infect Dis 1995, 171:61-67.
6. 6. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl Med 1995, 333:1534-1539.
7. 7. Stein DS, Fish DG, Bilello JA, et al. A 24-week open label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996, 10:485-492.
8. 8. Collier AC, Coombs RW, Schoenfeld DA, et al., AIDS Clinical Trials Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
9. 9. Hammer SM, Squires KE, Hughes MD, et al., AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997, 337:725-733.
10. 10. Cameron DW, Heath Chiozzi M, Danner S, et al., The Advanced HIV Disease Ritonavir Study Group. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1997, 351:543-549.
11. 11. Egger M, Hirschel B, Francioli P, et al., Swiss HIV Cohort Study. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997, 315: 1194-1199.
12. 12. Chiasson MA, Li W, Berenson L, et al. Declining AIDS mortality in New York City. XII International Conference, on AIDS. Geneva, June 1998 [abstract 13218].
13. 13. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998, 6:450-454.
14. 14. Detels R, Mun̄oz A, McFarlane G, et al., Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. J Am Med Assoc 1998, 17:1497-1503.
15. 15. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased disease progression of HIV in patients treated with saquinavir plus HIVID. XI International Conference on AIDS, Vancouver, July 1996 [abstract LB.B.6033].
16. 16. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
17. 17. Hessol NA, Koblin BA, van Griensven GJP, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1976-1991. Am J Epidemiol 1994, 139:1077-1007.
18. 18. Darby SC, Ewarl DW, Giangrande PL, Spooner RJ, Rizza CR, UK Haemophilia Centre Directors' Organisation. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996, 347:1573-1579.
19. 19. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion Br Med J 1996, 313:583-586.
20. 20. UK Register of HIV Seroconverters Steering Committee. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS 1998, 12:639-667.
21. 21. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
22. 22. Hamilton JD, Hartigan PM, Simberkoff MS, et al. and The Veterans Affairs AIDS Co-operative Study Group on AIDS treatment. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992, 7:437-443.
23. 23. UK Register of HIV Seroconverters Steering Committee. The UK Register of HIV Seroconverters: methods and analytical issues. Epidemiol Infect 1996, 117:305-312.
24. 24. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. 25. Clayton C, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993.
26. 26. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall; 1984.
27. 27. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc B 1972, 34:187-220.
28. 28. Pedersen C, Lindhardt BØ, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. Br Med J 1989, 299:154-157.
29. 6/I, AIDS, and death from AIDS? Br Med J 1994, 309:1535-537.
30. 30. Keet IPM, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters, AIDS 1993, 7:51-57.
31. 31. Phillips AN, Lee CA, Elford J, et al. The cumulative risk of AIDS as the CD4 lymphocyte count declines. J Acquir Immune Defic Syndr 1992, 5:148-152.
32. + T-cell counts. J Acquir Immune Defic Syndr 1991, 4:970-975.
33. 33. Rosenberg PS, Goedert JJ, Biggar RJ for the Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994, 8:803-510.
34. 34. Carré N, Deveau C, Belanger F, et al. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994, 8:797-802.
35. 35. Darby SC, Rizza CR, Doll R, et al. Incidence of AIDS and excess mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J 1989, 298:1064-1068.
36. 36. Brettle RP, McNeil AJ, Burns S, et al. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 1996, 10: 419-430.
37. 37. Porter K on behalf of the Steering Committee of the UK Register of HIV Sroconverters. Survival following HIV seroconversion -evidence of a recent change? XII Interntional Conference on AIDS. Geneva, June 1998 [abstract 11335].